ORCID as entered in ROS

Select Publications
2022, 'Gynaecological Cancer in Older Adults with Frailty', in Frailty in Older Adults with Cancer, pp. 447 - 466, http://dx.doi.org/10.1007/978-3-030-89162-6_25
,2021, 'Prevention of chemotherapy-induced peripheral neuropathy (CIPN): Current clinical data and future directions', in Diagnosis Management and Emerging Strategies for Chemotherapy Induced Neuropathy A Mascc Book, pp. 125 - 136, http://dx.doi.org/10.1007/978-3-030-78663-2_5
,2013, 'Pharmacology of Chemotherapy', in Stuart M Lichtman MD; Audisio RA (ed.), Management of Gynecological Cancers in Older Women, Springer Verlag
,2004, 'Supportive treatment in gynecologic malignancies', in Chemotherapy for Gynecological Neoplasms Current Therapy and Novel Approaches, pp. 233 - 244
,2000, 'Oral versus intravenous fluoropyrimidines for metastatic colorectal cancer.', in Strickland A (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd002889
,2000, 'Chemotherapy and radiotherapy for pancreatic cancer', in Yip D (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd002093
,2025, 'Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin', BMC Cancer, 25, http://dx.doi.org/10.1186/s12885-025-13506-4
,2025, 'Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary', Nature Communications, 16, http://dx.doi.org/10.1038/s41467-025-59661-x
,2025, 'Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study', Clinical Genitourinary Cancer, 23, http://dx.doi.org/10.1016/j.clgc.2025.102345
,2025, 'Will evidence-based patient-centred care meet the future inter-generational needs of older adults with cancer? A diverse perspective', Journal of Geriatric Oncology, 16, http://dx.doi.org/10.1016/j.jgo.2025.102241
,2025, 'Real-world implementation of geriatric assessment in cancer care among older adults: the role of implementation science frameworks', Current Opinion in Supportive and Palliative Care, 19, pp. 12 - 18, http://dx.doi.org/10.1097/SPC.0000000000000740
,2025, 'AGITG ASCEND: Randomised, double-blind phase II study of certepetide or placebo added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma: Initial results.', Journal of Clinical Oncology, 43, pp. 728 - 728, http://dx.doi.org/10.1200/jco.2025.43.4_suppl.728
,2024, 'Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study', Blood Advances, 8, pp. 5674 - 5682, http://dx.doi.org/10.1182/bloodadvances.2024014035
,2024, 'Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial', Lancet Oncology, 25, pp. 1135 - 1146, http://dx.doi.org/10.1016/S1470-2045(24)00334-6
,2024, 'Adequate assessment yields appropriate care—the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO/SIOG Cancer in the Elderly Working Group', ESMO Open, 9, http://dx.doi.org/10.1016/j.esmoop.2024.103657
,2024, 'Use of an emulated trial to investigate the association between use of nitrogen-based bisphosphonates and risk of epithelial ovarian cancer', International Journal of Epidemiology, 53, http://dx.doi.org/10.1093/ije/dyae108
,2024, 'Clinical impact of molecular profiling in the national prospective cohort Solving Unknown Primary Cancer (SUPER) study.', Journal of Clinical Oncology, 42, pp. 3056 - 3056, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3056
,2024, 'Age-friendly healthcare: integrating the 4Ms to enable age-friendly cancer care', Current Opinion in Supportive and Palliative Care, 18, pp. 9 - 15, http://dx.doi.org/10.1097/SPC.0000000000000687
,2024, 'Supportive and palliative care for older adults with cancer; facilitating person-centred, age friendly care', Current Opinion in Supportive and Palliative Care, 18, pp. 1 - 2, http://dx.doi.org/10.1097/SPC.0000000000000689
,2023, 'FEAR OF CANCER RECURRENCE IN OLDER WOMEN IN REMISSION FROM GYNAECOLOGICAL CANCER IN REGIONAL AUSTRALIA', Innovation in Aging, 7, pp. 1042 - 1042, http://dx.doi.org/10.1093/geroni/igad104.3349
,2023, 'THE ROLE OF AGE-FRIENDLY HEALTH CARE IN OLDER ADULTS WITH CANCER', Innovation in Aging, 7, pp. 198 - 198, http://dx.doi.org/10.1093/geroni/igad104.0651
,2023, 'The effect of comprehensive geriatric assessment on care received, treatment completion, toxicity, cancer-related and geriatric assessment outcomes, and quality of life for older adults receiving systemic anti-cancer treatment: A systematic review', Journal of Geriatric Oncology, 14, http://dx.doi.org/10.1016/j.jgo.2023.101585
,2023, 'Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort', Journal of Geriatric Oncology, 14, http://dx.doi.org/10.1016/j.jgo.2023.101621
,2023, 'Association between antihypertensive medicine use and risk of ovarian cancer in women aged 50 years and older', Cancer Epidemiology, 86, http://dx.doi.org/10.1016/j.canep.2023.102444
,2023, 'COVID-19 infection among patients with cancer in Australia from 2020 to 2022: a national multicentre cohort study', Lancet Regional Health Western Pacific, 38, http://dx.doi.org/10.1016/j.lanwpc.2023.100824
,2023, 'Geriatric Oncology in the Instagram Era: Feasibility and Acceptability Randomised Controlled Trial on Adopting PhotoVoice to Enable Empowerment, Patient-Centred Care, and Shared Decision Making—Study Protocol', Methods and Protocols, 6, http://dx.doi.org/10.3390/mps6040068
,2023, 'Defining research priorities and needs in cancer symptoms for adults diagnosed with cancer: an Australian/New Zealand modified Delphi study', Supportive Care in Cancer, 31, http://dx.doi.org/10.1007/s00520-023-07889-y
,2023, 'ASCEND: A randomised, double-blinded, phase II study of gemcitabine and nab‐paclitaxel with CEND‐1/LSTA1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.', Journal of Clinical Oncology, 41, pp. TPS4197 - TPS4197, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps4197
,2023, 'Circulating tumor DNA (ctDNA) as a marker of residual disease and recurrence in resected stage I-IV epithelial ovarian cancer (EOC).', Journal of Clinical Oncology, 41, pp. 5553 - 5553, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5553
,2023, 'Integrated care for older people with cancer: a primary care focus', Lancet Healthy Longevity, 4, pp. e243 - e245, http://dx.doi.org/10.1016/S2666-7568(23)00058-2
,2023, 'Olaparib in HR-deficient (HRD), metastatic triple-negative breast cancer (TNBC) and relapsed ovarian cancer (ROC) without germline mutations in BRCA1 or BRCA2: Phase 2 EMBRACE trial.', Journal of Clinical Oncology, 41, pp. e15079 - e15079, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e15079
,2023, 'Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation', European Journal of Cancer, 183, pp. 109 - 118, http://dx.doi.org/10.1016/j.ejca.2023.01.016
,2023, 'Supportive and palliative care for older adults with cancer', Current Opinion in Supportive and Palliative Care, 17, pp. 1 - 2, http://dx.doi.org/10.1097/SPC.0000000000000633
,2023, 'Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer', BJU International, 131, pp. 179 - 182, http://dx.doi.org/10.1111/bju.15930
,2023, 'Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary', Journal for Immunotherapy of Cancer, 11, http://dx.doi.org/10.1136/jitc-2022-005809
,2023, 'Perioperative Beta-Blocker Supply and Survival in Women with Epithelial Ovarian Cancer and a History of Cardiovascular Conditions', Journal of Clinical Oncology, 41, pp. 266 - 275, http://dx.doi.org/10.1200/JCO.22.00097
,2023, 'A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary', Journal of Pathology, 259, pp. 81 - 92, http://dx.doi.org/10.1002/path.6022
,2023, 'Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?', Expert Review of Pharmacoeconomics and Outcomes Research, 23, pp. 231 - 239, http://dx.doi.org/10.1080/14737167.2023.2161048
,2023, 'ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial', ESMO Gastrointestinal Oncology, 1, pp. 3 - 8, http://dx.doi.org/10.1016/j.esmogo.2023.07.001
,2023, 'Implementation of Enhanced Supportive Care for Older Adults at an Australian Regional Cancer Centre', Journal of Geriatric Oncology, 14, pp. S41 - S41, http://dx.doi.org/10.1016/s1879-4068(23)00339-9
,2022, 'IMPLEMENTING AND MEASURING IMPACT OF A FIVE-YEAR TRANSLATIONAL GERIATRIC ONCOLOGY RESEARCH PROGRAM', Innovation in Aging, 6, pp. 235 - 236, http://dx.doi.org/10.1093/geroni/igac059.934
,2022, 'Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site study', Supportive Care in Cancer, 30, pp. 8217 - 8229, http://dx.doi.org/10.1007/s00520-022-07228-7
,2022, 'Nitrogen-based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older (vol 114, djac050, 2022)', JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 114, pp. 1206 - 1206, http://dx.doi.org/10.1093/jnci/djac118
,2022, 'Nitrogen-based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older', Journal of the National Cancer Institute, 114, pp. 878 - 884, http://dx.doi.org/10.1093/jnci/djac050
,2022, 'Response to Lehrer and Rheinstein', JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, http://dx.doi.org/10.1093/jnci/djac083
,2022, 'Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial', Lancet Oncology, 23, pp. 362 - 373, http://dx.doi.org/10.1016/S1470-2045(21)00757-9
,2022, 'Supportive and palliative care for older adults with cancer', Current Opinion in Supportive and Palliative Care, 16, pp. 1 - 2, http://dx.doi.org/10.1097/SPC.0000000000000586
,2022, 'Exercise as a supportive care strategy in men with prostate cancer receiving androgen deprivation therapy at a regional cancer centre: a survey of patients and clinicians', Supportive Care in Cancer, 30, pp. 1379 - 1389, http://dx.doi.org/10.1007/s00520-021-06512-2
,2022, 'Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial', Annals of Oncology, 33, pp. 67 - 79, http://dx.doi.org/10.1016/j.annonc.2021.09.011
,2022, '165P Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer', Annals of Oncology, 33, pp. S1498 - S1499, http://dx.doi.org/10.1016/j.annonc.2022.10.202
,